Krsnaa Diagnost. Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹240 Cr +31.1% YoYSee revenue, profit and what management said. You are viewing Q1 FY27.
KD

Krsnaa Diagnost.

Q1 FY27Healthcare Services

Krsnaa Diagnostics Q1 FY27 earnings call: Revenue & Margins

Q1 FY27 earnings call: what management said on revenue, margins and capex.

Revenue
₹211Cr
+19.9% YoY
+22% QoQ
Net profit
₹16Cr
−20% YoY
−62.8% QoQ
Margin
27%
−2 pp YoY
−6 pp QoQ

What the Q1 FY27 call signalled

4 of 4 strong

RevenueGood growth
MarginMargins slightly up
CapexCapex planned
FundraiseFundraise planned
Price₹558
Market cap₹1.8K Cr
P/E17.7

The short version

Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19). Rajasthan PPP project revenues expected to double in Q2 FY27, with annualized revenue guidance of INR100-150 crores, potentially reaching INR200-250 crores in aspirational terms.

From Krsnaa Diagnost.'s Q1 FY27 earnings-call transcript · updated 23 Sept 2026.

Revenue & Sales Performance

Good growth
  • Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19).
  • Rajasthan PPP Project: Revenue expected to double in coming quarters with a full-year target of INR100-150 crores, and aspirational target of INR200-250 crores (Pages 8-9).
  • Retail Business: Currently contributing around 8-9% of sales, anticipated to grow exponentially by the end of the financial year driven by new wellness and illness packages (Pages 15-16, 19).
  • New Projects: Expansion with additional PPP projects in pipeline including Himachal Pradesh and scaling up of MRI centers expected to contribute to top-line growth (Pages 15, 12).

2 more points from Krsnaa Diagnost.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Krsnaa Diagnost. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • The company has raised funds via promoter infusion through warrants.
  • These funds are intended for capital expenditure related to ongoing projects and certain acquisitions planned by the company. (Page 10)
  • The infrastructure-led business model requires front-ended capital expenditure for building laboratories, installing equipment, and staffing teams before volume ramps up.
  • Investments have been made in building labs, diagnostic networks, and launching new MRI centers, especially highlighted in Rajasthan and other PPP projects. (Pages 5, 7, 12)

2 more points from Krsnaa Diagnost.'s call on capex

Create a free account to keep reading this call

Top-ranked in Healthcare Services

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
Rev 1Mar 3
3
Rev 2Mar 1
4
Rev 2Mar 1
5
Rev 2Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Krsnaa Diagnost. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

  • Rajasthan project is fully operational with 31 Mother labs, 62 hub labs, and 1,228 collection centers, offering significant future revenue visibility and scale.
  • Radiology expansion includes 17 MRI centers in the pipeline; 8 MRI centers in Maharashtra were inaugurated and operationalized in Q1 FY27.
  • Additional PPP projects in the pipeline beyond Rajasthan are expected to materialize and serve as new growth engines.
  • Retail business is expanding rapidly, with over 4,000 touchpoints across 7 states, leveraging an asset-light franchise model for growth.

2 more points from Krsnaa Diagnost.'s call on order book

Create a free account to keep reading this call

Krsnaa Diagnost. — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Krsnaa Diagnost. Q1 FY27 results — key figures

Krsnaa Diagnost. Q1 FY27 reported results vs Q1 FY26, ₹ crore
₹ CrQ1 FY27Q1 FY26YoYQ4 FY26QoQ
Revenue211176+19.9%173+22%
Operating profit (EBITDA)5750+14%570%
Operating margin27%29%-2 pp33%-6 pp
Profit before tax2226-15.4%54-59.3%
Net profit (PAT)1620-20%43-62.8%
EPS (₹)4.886.03-19.1%13.37-63.5%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹240 Cr, net profit ₹25 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Healthcare Services this season

  • Aatmaj Health (Q1 FY27)

    Revenue for Q1 FY 2026-27: ₹8.13 crore . Key investor presentation takeaways from Aatmaj Healthcare Ltd's Q1 FY27 investor presentation — and how it ranks again

  • Asarfi Hospital (Q1 FY27)

    Q1'FY27 consolidated revenue from operations: ₹47.5 Cr, up 32.8% YoY (vs ₹35.7 Cr in Q1'FY26) . Key investor presentation takeaways from Asarfi Hospital Ltd's Q

  • KMC Speciality (Q1 FY27)

    Q1 FY'27 Revenue from operations: INR 91.8 Cr, up 38% YoY from INR 66.6 Cr in Q1 FY'26. Key concall takeaways from KMC Speciality Hospitals (India) Ltd's Q1…

  • 3B Blackbio (Q1 FY27)

    Q1 2026-27 revenue from operations: ₹3,205.73 Lakh (including Coris sales of ₹862.83 Lakh) vs ₹1,996.06 Lakh in Q1 2025-26 — YoY growth approx. Key concall…

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Krsnaa Diagnost. and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Krsnaa Diagnost. Q1 FY27 results?

Volume Growth: Expected to continue growing both in retail and PPP segments, especially with underserved areas ramping up exponentially (Page 19). Rajasthan PPP project revenues expected to double in Q2 FY27, with annualized revenue guidance of INR100-150 crores, potentially reaching INR200-250 crores in aspirational terms.

What is Krsnaa Diagnost. share price analysis?

Krsnaa Diagnost. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 17.7 with a market cap of ₹1,755 Cr. Investors should review the full earnings analysis for detailed insights.

Is Krsnaa Diagnost. planning capital expenditure?

The company has raised funds via promoter infusion through warrants.

Keep Krsnaa Diagnost. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.